Ovarian Cancer

Skip Ribbon Commands
Skip to main content
    • Contact Us
    • One Hoag Drive,
      P.O. Box 6100
      Newport Beach, CA
      92658-6100
    • (949) 764-HOAG (4624)
    • feedback@hoag.org
    • Follow Us
    • Directory Listing
  • Ovarian Cancer

  • Contact Us - 800-701-HOAG (4624)
 

Overview
 
At Hoag, patients diagnosed with ovarian cancer have a better chance of surviving the cancer because Hoag's survival rates are better than the national average.*
 
A woman has two ovaries, which are walnut sized organs on both sides of the uterus.  The majority of ovarian cancers occur after menopause and originate from the surface (epithelial) cells of the ovary.  However, ovarian cancer can arise in younger women.  The lifetime risk for an American woman to develop ovarian cancer is 1 in 70.   Due to the absence of an effective screening test and the vague symptoms associated with the disease, ovarian cancer is many times diagnosed after it has spread in the abdominal cavity.

Risk Factors

The risk of ovarian cancer increases with age and peaks at about 70 years old.
 
Common risk factors include those conditions which are associated with increased ovulation:
 
  • Few pregnancies
  • Decreased fertility
  • Delayed child-bearing
  • A small portion of the population have an abnormal gene, which markedly increases their risk of ovarian and breast cancer.

Symptoms

Symptoms of ovarian cancer can include:
 
  • Nausea
  • Vomiting
  • Bloating
  • Abdominal pain
  • Change in bowel or bladder function

Treatment Options 

The standard treatment option for ovarian cancer includes surgery and possibly chemotherapy.

The most common surgical procedure is the removal of the involved ovary, lymph nodes, and the fatty apron in the abdomen (omentum). Depending on the age of the patient, the other ovary and uterus might be removed. In cases of advanced ovarian cancer, other organs may also be removed.

The decision regarding chemotherapy is made based on the extent of the disease, which is identified at the time of surgery.

Intraperitoneal Chemotherapy

An innovative treatment option available for Hoag ovarian cancer patients is Intraperitoneal Chemotherapy (IP Chemo). Standard Chemotherapy can be administered in a variety of ways including orally or intravenously – into a vein - whereas IP Chemo is delivered directly to the peritoneal or abdominal cavity  By targeting the abdominal cavity and ovaries, IP Chemo limits exposure to healthy tissues.  

 

How Intraperitoneal Chemotherapy Works

Traditionally, Chemotherapy for ovarian cancer has been given intravenously, but several studies have shown advantages to receiving IP chemotherapy for women with advanced ovarian cancer. The primary way ovarian cancer spreads is by releasing tumor cells in the abdominal cavity, which can attach to other organs and form new tumors. IP chemo delivers concentrated doses of chemotherapy directly to the abdominal area and ovaries. It is often given in combination with intravenous chemotherapy. It is given through a port or catheter, which is surgically implanted in the abdominal cavity. IP chemotherapy can be administered in an office setting.

IP chemotherapy should be given following surgical removal of all visible cancer, as it is most effecting in treating microscopic disease. It is associated with more side effects than intravenous chemotherapy. IP chemotherapy is most often used at the time of diagnosis of ovarian cancer, but in some cases may be used to treat recurrent cancer. Not every woman is a good candidate for IP chemo, but it should be considered as an option.

Another form of intraperitoneal treatment is Hyperthermic Intraperitoneal Chemotherapy, or HIPEC. This is a technique where heated chemotherapy is circulated for 90 minutes in the abdominal cavity. This is done under anesthesia in the operating room and is typically given only once. It has traditionally been used in treating colon cancer, and there is limited data on its effectiveness in ovarian cancer. However, small studies have shown promising results. HIPEC can be used in combination with a course of IP chemotherapy.   For more details please contact a Gynecologic Oncologist.



Patients who appear to have limited disease may be candidates for Minimally Invasive Surgery with either the robot or the laparoscope

As the largest volume gynecologic robotic program in Orange County, and the first multidisciplinary program of its kind in Southern California, Hoag’s Gynecologic Robotic Surgery Program utilizes the most advanced technology for minimally invasive surgery:  The da Vinci Surgical System.  Through the use of the da Vinci robot, Hoag’s expert team of physicians has greater mobility and visibility, allowing for a more precise surgery.  The robot also provides many benefits to the patient, including:
 
  • Less post-operative pain and scarring
  • Decreased blood loss and lower risk of blood transfusion
  • Lower risk of infection
  • Shorter hospital stay
  • Faster return to normal activities
 
Patient Resources 
 
Winning Against Ovarian Cancer
 
For more than a decade, Hoag Cancer Center has been the leading provider for the treatment for women with gynecologic malignancies in Orange County, including cancer of the ovary. With a multidisciplinary approach that includes prevention, early detection, the use of promising new therapies, participation in laboratory and clinical research, and extensive complementary care, the team at Hoag Cancer Center provides ovarian cancer patients with every diagnostic and therapeutic advantage. Learn more about Hoag's diagnostic and therapeutic advantages

Download the Gynecologic Cancer Care PDF.
 
GYN Cancer Care PDF 


* Data per Hoag Cancer Registry and SEER (1999-2006). SEER (Surveillance, Epidemiology and End Results Program) a premier source for cancer statistics in the United States.

 

 Content Editor ‭[3]‬

 
 

 Content Editor ‭[2]‬